DAFTAR PUSTAKA

1. de Araújo RA, Cordero da Luz FA, da Costa Marinho E, Mendes TR, Nascimento CP, Ribeiro Delfino PF, et al. Operable breast cancer: How not to worsen the prognosis, especially in triple negative and stage II tumors. Surg Oncol. 2021 Sep 1;38.
2. Qin YY, Li H, Guo XJ, Ye XF, Wei X, Zhou YH, et al. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: A meta-analysis of 19 randomized trials with 30698 patients. PLoS One. 2011 Nov 1;6(10).
3. Cancer Today [Internet]. GLOBOCAN. 2020 [cited 2022 Sep 13]. Available from: https://gco.iarc.fr/
4. Dinas Kesehatan Provinsi Sumatera Barat. Profil Dinas Kesehatan tahun 2017. Padang: Dinkes SUMBAR; 2018.
5. Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, et al. Breast cancer, version 3.2020. JNCCN Journal of the National Comprehensive Cancer Network. 2020 Apr 1;18(4):452–78.
6. Komite Nasional Penanggulangan Kanker. Panduan Nasional Penanganan Kanker: Kanker Payudara. Padang: Kementrian Kesehatan Republik Indonesia; 2015.
7. Cianfrocca M, Lori Goldstein DJ. Operable Breast Cancer. Curr Treat Options Oncol. 2001;1:157–67.
8. Fentiman IS. Management of operable breast cancer in older women. Journal of the Royal Society of Medicine, Supplement. 2013 Jan;106(1):13–8.
9. Moo TA, Sanford R, Dang C, Morrow M. Overview of Breast Cancer Therapy. PET Clin. 2018 Jul 1;13(3):339–54.

10. Spring LM, Bar Y, Isakoff SJ. The Evolving Role of Neoadjuvant Therapyfor Operable Breast Cancer. JNCCN Journal of the National Comprehensive Cancer Network. 2022 Jun 1;20(6):723–34.

11. Mamounas EP. Neoadjuvant chemotherapy for operable breast cancer: Is this the future? Clin Breast Cancer. 2003;4(SUPPL. 1).

12. Okines AFC, Kipps E, Irfan T, Coakley M, Angelis V, Asare B, et al. Impact of timing of adjuvant chemothapy for early breast cancer: the Royal Marsden Hospital experience. Br J Cancer. 2021 Jul 20;125(2):299–304.

13. Handojo D, et al. Konsensus Terapi Sistemik. Perhimpunan Ahli Bedah Onkologi Indonesia. 2020. Hal 7-8.

14. Abu Samaan TM, Samec M, Liskova A, Kubatka P, Büsselberg D. Paclitaxel‘s Mechanistic and Clinical Effects on Breast Cancer. Biomolecules. 2019 Nov27;9(12).

15. Abotaleb M, Kubatka P, Caprnda M, Varghese E, Zolakova B, Zubor P,et al. Chemotherapeutic agents for the treatment of metastatic breast cancer: An update.Biomedicine and Pharmacotherapy. 2018 May 1;101: 458–77.

16. Abdulmuthalib, Darwis I, Prayogo N, Sutjipto. First-line chemotherapy of advanced or metastatic breast cancer (MBC) with docetaxel and doxorubicin in Indonesia: results from A phase II trial. Med J Indones. 2005; 14(1): 20-5.

17. Kenmotsu H, Tanigawara Y. Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose. *Cancer Sci*. 2015;106(5):497-504. doi:10.1111/cas.12647

18. Khairan S, Keban SA, Afrianty M. Evaluasi Efek Samping Obat Kemoterapi terhadap Quality of Life (QoL) Pasien Kanker Payudara di Rumah Sakit X Jakarta. Jurnal Ilmu Kefarmasian Indonesia. 2019;17(1):9–13.

19. Prieto-Callejero B, Rivera F, Fagundo-Rivera J, Romero A, Romero-Martín M, Gómez-Salgado J, et al. Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer. Medicine. 2020 Aug 14;99(33):e21695.

20. Imran M, Saleem S, Chaudhuri A, Ali J, Baboota S. Docetaxel: An update on its molecular mechanisms, therapeutic trajectory and nanotechnology in the treatment of breast, lung and prostate cancer. Journal of Drug Delivery Science and Technology. 2020(60)

21. Salminen E, Bergman M, Huhtala S, Jekunen A, Ekholm E. Docetaxel, a promising novel chemotherapeutic agent in advanced breast cancer. Anticancer Res. 2000;20(5C):3663-3668.

22. Nascimento RG do, Otoni KM. Histological and molecular classification of breastcancer: what do we know? Mastology. 2020;30.

23. Smolarz B, Zadrożna Nowak A, Romanowicz H. Breast Cancer— Epidemiology, Classification, Pathogenesis and Treatment (Review ofLiterature). Cancers (Basel). 2022 May 1;14(10).

24. Harbeck, N., & Jakesz, R. (2007). St. Gallen 2007: Breast cancer treatment consensus report. *Breast Care, 2*(3), 130–134. https://doi.org/10.1159/000103629

25. Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—An updated review. Cancers (Basel). 2021 Sep 1;13(17).

26. International Agency for Research on Cancer. GLOBOCAN: Indonesia. 2021.

27. Henderson JA, Duffee D, Ferguson T. Breast Examination Techniques. [Updated 2023

Jan 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from:https://www.ncbi.nlm.nih.gov/books/NBK459179/

28. Kalli S, Semine A, Cohen S, Naber SP, Makim SS, Bahl M. American joint committee on cancer‘s staging system for breast cancer, eighth edition: What the radiologist needs to know. Radiographics. 2018 Nov 1;38(7):1921–33.
29. Koh J, Kim MJ. Introduction of a new staging system of breast cancer for radiologists: An emphasis on the prognostic stage. Korean J Radiol. 2019 Jan 1;20(1):69–82.
30. Wang W. Radiotherapy in the management of early breast cancer. J Med Radiat Sci. 2013 Mar 3;60(1):40–6.
31. Haussmann J, Corradini S, Nestle-Kraemling C, Bölke E, Njanang FJD,Tamaskovics B, et al. Recent advances in radiotherapy of breast cancer. RadiationOncology. 2020 Dec 30;15(1):71.
32. Cox J, Bhatti A, Graham Y, Lee D. Update on breast cancer diagnosis and management: New topics for primary care. British Journal of General Practice. 2020 Oct 1;70(699):515–6.
33. Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA - Journal of theAmerican Medical Association. 2019 Jan 22;321(3):288–300.
34. Amjad MT, Chidharla A, Kasi A. Cancer Chemotherapy. StatPearlsPublishing. 2022.
35. Shields M. Chemotherapeutics. In: Pharmacognosy: Fundamentals, Applications and Strategy. Elsevier Inc.; 2017. p. 295–313.
36. Sarder, A., Rabbani, M. G., Chowdhury, A. S. M. H. K., & Sobhani, M.-E. (2015). Molecular Basis of Drug Interactions of Methotrexate, Cyclophosphamide and 5-Fluorouracil as Chemotherapeutic Agents inCancer. *Biomedical Research and Therapy, 2*(2). https://doi.org/10.7603/s40730-015-0005-1

37. Riedel F, Hoffmann AS, Moderow M, Heublein S, Deutsch TM, Golatta M, et al. Time trends of neoadjuvant chemotherapy for early breast cancer. IntJ Cancer.2020 Dec 1;147(11):3049–58.

38. Patiniott PD, Wong GYM, Lam YH, Fosh B. Neoadjuvant chemotherapy rates for breast cancer in Australia—–are we there yet?‖ Annals of Breast Surgery. 2019 Apr;3:9–9.

39. Bethesda. LiverTox: Clinical and Research Information on Drug-InducedLiver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. p. Taxanes. Available from:https://www.ncbi.nlm.nih.gov/books/NBK548797/

40. Kadakia A, Rajan SS, Abughosh S, Du XL, Johnson ML. CMF-regimen preferred as first-course chemotherapy for older and sicker women with breastcancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. Lippincott Williams and Wilkins; 2015. p. 165–73.

41. Nurgali K, Jagoe RT, Abalo R. Editorial: Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae?Front Pharmacol. 2018 Mar 22;9(MAR).

42. Suganya Kanagaraj, Sumathi Sundaravadivelu. The Anticancer Drugs in Breast Cancer: Pharmacodynamics and Adverse Effects. Indian Journal of Natural Sciences [Internet]. 2022;12(70):39102–14. Available from: www.tnsroindia.org.in

43. Gupta K, Walton R, Kataria SP. Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Recommendations, and New Trends. Cancer Treat Res Commun. 2021

44. Wang J, Lu Z, Au JLS. Protection Against Chemotherapy-Induced Alopecia. Pharm Res. 2006;23(11).American Pharmacist Association. Drug Information Handbook 21st ed.

United States: Lexi-Comp Inc; 2012

45. Was H, Borkowska A, Bagues A, Tu L, Liu JYH, Lu Z, et al. Mechanisms of Chemotherapy-Induced Neurotoxicity. Front Pharmacol. 2022 Mar 28;13.

46. van der Zanden SY, Qiao X, Neefjes J. New insights into the activities and toxicities of the old anticancer drug doxorubicin. FEBS Journal. 2021 Nov 1;288(21):6095–111.

47. Perez IE, Taveras Alam S, Hernandez GA, Sancassani R. Cancer Therapy- Related Cardiac Dysfunction: An Overview for the Clinician. Clin Med Insights Cardiol. 2019 Jan 29;13:117954681986644.

48. Fontanella C, Bolzonello S, Lederer B, Aprile G. Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropenia. Breast Care. 2014 May 22;9(4):239–45

49. das A, Ranadive N, Kinra M, Nampoothiri M, Arora D, Mudgal J. An Overview on Chemotherapy-induced Cognitive Impairment and Potential Role of Antidepressants. Curr Neuropharmacol. 2020;18:838–51.

50. Yazdani-Charati R, Hajian-Tilaki K, Sharbatdaran M. Comparison of pathologic characteristics of breast cancer in younger and older women. *Caspian J Intern Med.* 2019;10(1):42-47. doi:10.22088/cjim.10.1.42

51. Dokcu S, Caparlar MA, Basceken SI, Eroglu A. Distribution and Clinicopathological Characteristics of Breast Cancer Molecular Subtypes in Turkish Women. *European Journal of Clinical Medicine. 2022; 3(6): 14-20.*

52. Zanuso V, Fregoni V, Gervaso L. Side effects of adjuvant chemotherapy and their impact on outcome in elderly breast cancer patients: a cohort study. *FutureSci.OA*.2020;6(9)

53. Paramita S, Raharjo EN, Niasari M, Azizah F, Hanifah NA. Luminal B is the Most

Common Intrinsic Molecular Subtypes of Invasive Ductal Breast Carcinoma Patients in East Kalimantan, Indonesia. *Asian Pac J Cancer Prev*. 2019;20(8):2247-2252. Published 2019 Aug 1. doi:10.31557/APJCP.2019.20.8.2247

54. Jääskeläinen A, Roininen N, Karihtala P, Jukkola A. High Parity Predicts Poor Outcomes in Patients With Luminal B-Like (HER2 Negative) Early Breast Cancer: A Prospective Finnish Single-Center Study. *Front Oncol*. 2020;10:1470. Published 2020 Aug 14. doi:10.3389/fonc.2020.01470
55. Li ZH, Hu PH, Tu JH, Yu NS. Luminal B breast cancer: patterns of recurrence and clinical outcome. *Oncotarget*. 2016;7(40):65024-65033. doi:10.18632/oncotarget.11344
56. Davey MG, Hynes SO, Kerin MJ, Miller N, Lowery AJ. Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer. *Cancers* 2021, *13*,4455 _
57. Gregorio A, Janni W, Friedl TW, Nitz U, Rack B, Schneeweiss A, dkk. The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C. British Journal of Cancer. 2022; 126:1715–1724
58. Willson ML, Burke L, Ferguson T, Ghersi D, Nowak AK, Wilcken N. Taxanes for adjuvant treatment of early breast cancer. *Cochrane Database Syst Rev*. 2019;9(9):CD004421. Published 2019 Sep 2. doi:10.1002/14651858.CD004421.pub3
59. Pearce A, Haas M, Viney R, et al. Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study. *PLoS One*. 2017;12(10):e0184360. Published 2017 Oct 10. doi:10.1371/journal.pone.0184360
60. Johnson-Arbor K, Dubey R. Doxorubicin. [Updated 2022 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan

Available from: https://www.ncbi.nlm.nih.gov/books/NBK459232/

61. Peter S, Alven S, Maseko RB, Aderibigbe BA. Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review. *Molecules*. 2022;27(14):4478. Published 2022 Jul 13. doi:10.3390/molecules27144478

62. Eide S, Feng Z. Doxorubicin chemotherapy-induced ‐chemo-brain‖: Meta- analysis. European Journal of Pharmacology. 2020: 881

63. Ajaykumar C. Overview on the Side Effects of Doxorubicin [Internet]. Advances in Precision Medicine Oncology. IntechOpen; 2021. Available from: http://dx.doi.org/10.5772/intechopen.94896

64. Thorn CF, Oshiro C, Marsh S, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. *Pharmacogenet Genomics*. 2011;21(7):440-446. doi:10.1097/FPC.0b013e32833ffb56

65. Liu Y, Hiramoto B, Kwok J, et al. Taxane-Induced Upper Gastrointestinal Bleeding. *Case Rep Oncol*. 2021;14(3):1373-1379. Published 2021 Sep 21. doi:10.1159/000517818

66. Cheng HL, Molassiotis A, Leung AKT, Wong KH. Docetaxel-Induced Peripheral Neuropathy in Breast Cancer Patients Treated with Adjuvant or Neo-Adjuvant Chemotherapy. *Breast Care (Basel)*. 2021;16(3):269-275.doi:10.1159/000507843

67. Abal M, Andreu JM, Barasoain I. Taxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of Action. *Current Cancer Drug Targets*, 2003, *3*, 193-203

68. Harvey V, Mouridsen H, Semiglazov V, Jakobsen E, Voznyi E, Robinson B, et al. Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer. JOURNAL OF CLINICAL ONCOLOGY. 2006; 24: 31

69. Zheng R, Han S, Duan C, et al. Role of taxane and anthracycline combinationregimens in the management of advanced breast cancer: a meta-analysis of randomized trials. *Medicine*

(Baltimore). 2015;94(17):e803.doi:10.1097/MD.0000000000000803

70. Adeel M, Asif M, Faisal MN, Chaudary MH, Malik MS, Khalid M. Comparative study of adjuvant chemotherapeutic efficacy of docetaxel plus cyclophosphamide and doxorubicin plus cyclophosphamide in female breast cancer. *Cancer Manag Res*. 2019;11:727-739. Published 2019 Jan 15. doi:10.2147/CMAR.S180802

71. Hirata T, Ozaki S, Tabata M, Iwamoto T, Hinotsu S, Hamada A, dkk. A Multicenter Study of Docetaxel at a Dose of 100 mg/m^2 in Japanese Patients with Advanced or Recurrent Breast Cancer. Intern Med. 2021; 60: 1183-1190

72. Kim K, Oh I, Ban H, Cho H, Kwon Y, Kim Y, dkk. Comparison of docetaxel/cisplatin dosages of 75/60 and 60/60 mg/m^2 for the treatment of non-small cell lung cancer. EXPERIMENTAL AND THERAPEUTIC MEDICINE. 2012; 4: 317-322

73. Ando M, Watanabe T, Nagata K, Narabayashi M, Adachi I, Katsumata N. Efficacy of Docetaxel 60 mg/m^2 in Patients With Metastatic Breast Cancer According to the Status of Anthracycline Resistance. J Clin Oncol. © 2001; 19:336-342.